Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio.
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Pract Radiat Oncol. 2021 Nov-Dec;11(6):480-487. doi: 10.1016/j.prro.2021.07.004. Epub 2021 Jul 22.
Vertebral compression fractures (VCF) are a common and severe complication of spine stereotactic body radiation therapy (SBRT). We sought to analyze how volumetric dosimetry and clinical factors were associated with the risk of VCF.
We evaluated 173 spinal segments that underwent single fraction SBRT in 85 patients from a retrospective database. Vertebral bodies were contoured and dosimetric values were calculated. Competing risk models were used to evaluate the effect of clinical and dosimetry variables on the risk of VCF.
Our primary endpoint was development of a post-SBRT VCF. New or progressive fractures were noted in 21/173 vertebrae (12.1%); the median time to fracture was 322 days. Median follow-up time was 426 days. Upon multivariable analysis, the percentages of vertebral body volume receiving >20 Gy and >24 Gy were significantly associated with increased risk of VCF (hazard ratio, 1.036, 1.104; P = .029, .044, respectively). No other patient or treatment factors were found to be significant on multivariable analysis. Sensitivity analysis revealed that the percentages of vertebral body volume receiving >20 Gy and >24 Gy required to obtain 90% sensitivity for predicting vertebral body fracture were 24% and 0%, respectively.
VCF is a common complication after SBRT, with a crude incidence of 12.1%. Treatment plans that permit higher volumes receiving doses >20 Gy and >24 Gy to the vertebral body are associated with increased risk of VCF. To achieve 90% sensitivity for predicting VCF post-SBRT, the percentage of vertebral volume receiving >20 Gy should be <24% and maximum point dose should be <24 Gy. These results may help guide clinicians when evaluating spine SBRT treatment plans to minimize the risk of developing posttreatment VCF.
脊柱立体定向体部放射治疗(SBRT)后椎体压缩性骨折(VCF)是一种常见且严重的并发症。我们旨在分析容积剂量学和临床因素与 VCF 风险的相关性。
我们从回顾性数据库中评估了 85 名患者的 173 个脊柱节段,这些节段接受了单次 SBRT。对椎体进行轮廓勾画并计算剂量学值。采用竞争风险模型评估临床和剂量学变量对 VCF 风险的影响。
我们的主要终点是 SBRT 后发生 VCF。173 个椎体中有 21 个(12.1%)出现新发或进展性骨折;骨折的中位时间为 322 天。中位随访时间为 426 天。多变量分析显示,椎体体积接受 >20 Gy 和 >24 Gy 的百分比与 VCF 风险增加显著相关(危险比,1.036,1.104;P=0.029,0.044)。多变量分析未发现其他患者或治疗因素有显著意义。敏感性分析显示,预测椎体骨折的 90%灵敏度所需的椎体体积接受 >20 Gy 和 >24 Gy 的百分比分别为 24%和 0%。
SBRT 后 VCF 是一种常见并发症,发生率为 12.1%。允许更高体积的椎体接受 >20 Gy 和 >24 Gy 剂量的治疗计划与 VCF 风险增加相关。为了达到预测 SBRT 后 VCF 的 90%灵敏度,接受 >20 Gy 的椎体体积百分比应<24%,最大点剂量应<24 Gy。这些结果可能有助于指导临床医生评估脊柱 SBRT 治疗计划,以最大限度地降低治疗后发生 VCF 的风险。